2 Minute Medicine: Pharma Roundup – Breakthrough ALS gene therapy, new adult pneumonia vaccine, needle-free obesity treatment, and Pfizer’s business overhaul [October 28, 2025]

Amryta’s Sodesta gene therapy gains accelerated approval for ALS

The Food and Drug Administration has granted accelerated approval to Sodesta, a one-time gene therapy targeting amyotrophic lateral sclerosis caused by SOD1 mutations. The treatment uses an intrathecal AAV vector to suppress the toxic protein driving motor neuron degeneration. In pivotal studies, Sodesta slowed functional decline by about 25 percent over one year compared with placebo. Roughly two percent of ALS patients carry a pathogenic SOD1 variant. Safety data showed mostly transient headache, fever, and aseptic meningitis-like symptoms that resolved without lasting complications. The FDA is requiring a post-marketing confirmatory trial to assess long-term survival benefit. European submission is planned for early 2026. Analysts expect modest commercial revenue but meaningful momentum for gene therapy in neurodegenerative disease. For clinicians, Sodesta reinforces that CNS gene delivery can achieve measurable functional preservation in ALS.

Merck’s V116 adult pneumococcal vaccine approved by the FDA

The FDA has approved Merck’s V116 pneumococcal vaccine, the first conjugate vaccine developed specifically for adults rather than adapted from pediatric formulations. A companion FDA review document confirms that the vaccine includes eight serotypes not covered by Prevnar 20 and directly reflects adult disease epidemiology (FDA clinical review). Public health planning is already underway with early policy language previewed in a CDC Advisory Committee summary. Clinicians expect rapid uptake among older adults and those with chronic cardiac or pulmonary disease. Manufacturing has been scaled ahead of 2026 demand. The approval is being viewed as a modernization of pneumococcal prevention strategy tailored to adult risk patterns. Updated CDC guidance is anticipated following the formal ACIP vote.

Lilly clears production hurdles ahead of oral GLP-1 pill launch

Eli Lilly has resolved manufacturing capacity issues that threatened the rollout timeline for its first oral GLP-1 receptor agonist, orforglipron. Clinical data submitted to regulators show durable 9 to 15 percent weight loss without injections or refrigeration requirements. Lilly’s expansion progress was confirmed in a Reuters regulatory update, with FDA submission expected later this year. Trial materials released by Lilly also document lower discontinuation rates than injectable GLP-1s, as outlined in a corporate investor summary. Analysts expect strong demand once available for patients unwilling to self-inject. Clinicians anticipate widespread primary-care adoption given simplified logistics of prescribing. If approved, orforglipron would represent a major expansion of needle-free obesity therapy.

Pfizer restructures into separate Oncology and Internal Medicine units

Pfizer is reorganizing into two core business segments, Oncology and Internal Medicine,  in a strategic shift aimed at accelerating late-stage development and portfolio prioritization. The move was confirmed in a Pfizer earnings and restructuring disclosure outlining transition steps for 2025 and 2026. A follow-up regulatory filing detailed divisional autonomy for budgeting and portfolio decisions. Oncology is expected to concentrate on antibody-drug conjugates and targeted therapies, while Internal Medicine will focus on cardiometabolic and inflammatory assets. The company will reduce redundant commercial roles during implementation. Analysts say this mirrors broader post-pandemic restructuring trends in large pharma. Operational realignment is expected to shorten regulatory preparation timelines and increase disease-specific engagement with clinicians.

Image: PD

©2025 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.